A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2...

Area of Science:

• Virology
• Vaccinology
• Molecular Biology

Background:

• Human parainfluenza virus type 2 (hPIV2) is a common virus with low pathogenicity.
• Developing safe and effective recombinant viral vectors is crucial for vaccine innovation.
• Existing vectors may have limitations in antigen loading and immunogenicity.

Purpose of the Study:

• To engineer a recombinant BC-PIV vector derived from hPIV2 for vaccine development.
• To evaluate the efficient loading of ectopic proteins and antigenic peptides onto the vector.
• To assess the immunogenicity of the BC-PIV vector carrying viral and tumor antigens.

Main Methods:

• Utilized reverse genetics to produce F gene-defective BC-PIV vectors.
• Loaded ectopic proteins and antigenic peptides onto the vector envelope (inside, outside, or both).
• Inserted genes for Ebola virus GP, melanoma gp100, and WT1 tumor antigen into the vector.
• Assessed antibody and T-cell responses in mouse models.

Main Results:

• Ectopic proteins with proper steric structure were efficiently loaded onto the BC-PIV vector.
• Ectopic antigenic peptides were successfully loaded onto the vector envelope.
• BC-PIV carrying the Ebola virus GP gene elicited neutralizing antibodies in mice.
• BC-PIV with melanoma gp100 and WT1 epitopes induced CD8+ T-cell responses in mice.

Conclusions:

• The engineered BC-PIV vector is a versatile and safe platform for recombinant vaccine development.
• The vector demonstrates efficient antigen loading and elicits relevant immune responses.
• This approach holds promise for addressing unmet medical needs in vaccine development.